Donor major histocompatibility complex class I expression determines the outcome of prenatal transplantation
Section snippets
Mice
Breeding stock for inbred strains of mice B6.Ly5.2 (H2b, Ly5.2+), SJL/J (H2s, Ly5.1+) (The Jackson Laboratories, Bar Harbor, Me), Balb/c (H2d, Ly5.2+) (Charles River Laboratories, Wilmington, Mass), and B6.TAP−/− (H2b, Ly5.2+) (Taconic, Germantown, NY) were purchased and bred in our colony. CSJLF1 (Balb/c × SJL/J F1, H2s/d, Ly5.1+Ly5.2+) mice were bred in our colony. Animals were mated and inspected daily for introital plugging. Day of plug was noted as day zero for time-dated pregnancies. All
The presence or absence of MHC class I expression by the donor cells does not affect survival or lead to graft-vs-host-disease
Four murine strains were selected to evaluate the allogeneic host response to MHC class I expression after IUCT (Fig. 1). The B6.Ly5.2 strain carries the H2b haplotype and is fully allogeneic with Balb/c recipients that bear the H2d haplotype. The B6.TAP−/− donor strain was chosen for the experimental group because it is deficient in the transporter associated with antigen presentation (TAP) and therefore does not express any MHC class I antigen but are otherwise identical with the parent
Discussion
The bias of IUCT that has existed for many years is that transplantation before the development of the adaptive immune system results in long-term donor-specific tolerance. However, the limited success of IUCT in clinical cases that do not involve immunodeficiency diseases forces a closer examination of this central dogma [9]. Recently, it has been postulated that an allogeneic barrier to the development of fetal tolerance may exist because of differences in donor cell MHC expression [4]. The
References (24)
- et al.
In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDXI)
Lancet
(1996) - et al.
In utero hematopoietic stem cell transplantation: ontogenic opportunities and biologic barriers
Blood
(1999) - et al.
Evidence for an immune barrier after in utero hematopoietic-cell transplantation
Blood
(2007) - et al.
Ontogenic changes in CD95 expression on human leukocytes: prevalence of T-cells expressing activation markers and identification of CD95-CD45RO+ T-cells in the fetus
Dev Comp Immunol
(2003) - et al.
Microchimerism and tolerance after in utero bone marrow transplantation in mice
J Surg Res
(1998) - et al.
Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells
Blood
(2006) Development and tolerance of natural killer cells
Curr Opin Immunol
(1999)- et al.
Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation
Blood
(1999) - et al.
Treatment of X-linked severe combined immunodeficiency by in utero transplantation of paternal bone marrow
N Engl J Med
(1996) - et al.
Prenatal transplantation of cytokine-stimulated marrow improves early chimerism in a resistant strain combination but results in poor long-term engraftment
Exp Hematol
(2006)
In utero bone marrow transplantation induces donor-specific tolerance by a combination of clonal deletion and clonal anergy
J Pediatr Surg
In utero stem cell transplantation
Semin Reprod Med
Cited by (5)
Engraftment of mouse amniotic fluid-derived progenitor cells after in utero transplantation in mice
2015, Journal of the Formosan Medical AssociationCitation Excerpt :By contrast, the immunomodulatory properties of AFPCs have been demonstrated in vitro but not in vivo, and therefore, the real scenario requires verification. Donor cells may have been rejected by the host because of donor cell-membrane surface antigens.34 It was also reported that donor cell migration in the uterine microenvironment may be inhibited by maternal T cells and maternal alloantibody.35,36
Challenges in Allogeneic Mesenchymal Stem Cell-Mediated Cardiac Repair
2010, Trends in Cardiovascular MedicineCitation Excerpt :Moreover, cell surface antigen expression can be manipulated either genetically or pharmacologically. For example, some studies have eliminated MHC-I expression in donor cells, although this did not appear to increase engraftment but, rather, led to rejection of the implanted cells (Durkin et al. 2008). However, a possible reason for this observation is the loss of the immunosuppressive MHC-Ib subtype along with the immunogenic MHC-Ia subtype (Rodgers and Cook 2005).
NK cell tolerance as the final endorsement of prenatal tolerance after in utero hematopoietic cellular transplantation
2015, Frontiers in PharmacologyIn utero hematopoietic stem cell transplantation for congenital disorders
2013, Human Fetal Tissue TransplantationMaternal T cells limit engraftment after in utero hematopoietic cell transplantation in mice
2011, Journal of Clinical Investigation
Presented at the 59th Annual Meeting of the Section on Surgery, American Academy of Pediatrics, San Francisco, CA, October 25-27, 2007.